Meeting
2018 ASCO Annual Meeting
Ultra-low doses of TX-004HR to improve symptoms of vulvar and vaginal atrophy (VVA) while maintaining serum levels of estradiol within the normal postmenopausal range.
Authors
Shari Beth Goldfarb
Memorial Sloan Kettering Cancer Center, New York, NY
Shari Beth Goldfarb , Jeanne Carter , Brian Bernick , Sebastian Mirkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Late and Long-Term Effects
Clinical Trial Registration Number
NCT02253173
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10074)
DOI
10.1200/JCO.2018.36.15_suppl.10074
Abstract #
10074
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
First Author: Allison M Quick
Poster
2017 ASCO Annual Meeting
Phase II study of the effect of the topical corticosteroid fluocinonide in patients on endocrine therapy for breast cancer or breast cancer prevention with symptoms of vaginal dryness and dyspareunia.
First Author: Evthokia A. Hobbs
Poster
2014 Breast Cancer Symposium
Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors.
First Author: Rebecca L. Glaser
Poster
2014 ASCO Annual Meeting
Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer.
First Author: Lee Steven Schwartzberg